Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF. Approved in 2021 based on data from the FIDELIO-DKD and FIGARO-DKD trials, Bayer announced on August 05, 2024 the FINEARTS-HF trial had met its primary endpoint

1042 Cross-Cultural Adaptation and Psychometric Validation of the Danish and Norwegian Versions of the Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM) Tine Rosenberg 1 , Claudia Rutherford 2 , Tracy King 3 , Margaret-Ann Tait 2 , Frida Bugge Askeland 4 , Lene Kongsgaard Nielsen 1 1 Quality of Life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark, 2 Cancer Care Research Unit, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, 3 Clinical Research Fellow, Cancer Care Research Unit, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, 4 Institute of Clinical Medicine, University of Oslo, Oslo, Norway Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :1042 Aims To translate and culturally adapt the Australian developed Steroid Symptom Questionnaire for Multiple Myeloma (SSQ-MM) into Danish and Norwegian and to evaluate the psychometric properties of the Norwegian version in newly diagnosed patients with MM

Professional Team : Experienced practitioners specializing in peptide therapies
Nausea and diarrhea were common gastrointestinal side effects that occasionally caused people to stop taking the medication
Convenient telehealth process : The entire process from the medical questionnaire to prescription approval and medication delivery is done online, eliminating the need for in-person doctor visits
Was the experiment independently replicated